ALKERMES PLC (ALKS) Fundamental Analysis & Valuation

NASDAQ:ALKS • IE00B56GVS15

28.45 USD
-0.18 (-0.63%)
At close: Mar 9, 2026
28.45 USD
0 (0%)
After Hours: 3/9/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ALKS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 519 industry peers in the Biotechnology industry. ALKS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ALKS has a correct valuation and a medium growth rate. This makes ALKS very considerable for quality investing!


Dividend Valuation Growth Profitability Health

7

1. ALKS Profitability Analysis

1.1 Basic Checks

  • ALKS had positive earnings in the past year.
  • ALKS had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: ALKS reported negative net income in multiple years.
  • Each year in the past 5 years ALKS had a positive operating cash flow.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • The Return On Assets of ALKS (9.72%) is better than 93.64% of its industry peers.
  • ALKS has a Return On Equity of 13.28%. This is amongst the best in the industry. ALKS outperforms 93.83% of its industry peers.
  • With an excellent Return On Invested Capital value of 10.90%, ALKS belongs to the best of the industry, outperforming 94.41% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for ALKS is in line with the industry average of 19.44%.
  • The 3 year average ROIC (18.21%) for ALKS is well above the current ROIC(10.90%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS has a better Profit Margin (16.37%) than 92.49% of its industry peers.
  • ALKS's Operating Margin of 17.21% is amongst the best of the industry. ALKS outperforms 93.45% of its industry peers.
  • The Gross Margin of ALKS (86.69%) is better than 88.63% of its industry peers.
  • In the last couple of years the Gross Margin of ALKS has remained more or less at the same level.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ALKS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ALKS is creating value.
  • Compared to 1 year ago, ALKS has more shares outstanding
  • The number of shares outstanding for ALKS has been increased compared to 5 years ago.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ALKS has an Altman-Z score of 5.47. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
  • ALKS's Altman-Z score of 5.47 is fine compared to the rest of the industry. ALKS outperforms 73.99% of its industry peers.
  • ALKS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.47
ROIC/WACC1.42
WACC7.7%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.55 indicates that ALKS has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.55, ALKS perfoms like the industry average, outperforming 41.23% of the companies in the same industry.
  • A Quick Ratio of 3.19 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS's Quick ratio of 3.19 is on the low side compared to the rest of the industry. ALKS is outperformed by 61.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALKS Growth Analysis

3.1 Past

  • The earnings per share for ALKS have decreased strongly by -40.76% in the last year.
  • Measured over the past years, ALKS shows a very strong growth in Earnings Per Share. The EPS has been growing by 31.92% on average per year.
  • ALKS shows a decrease in Revenue. In the last year, the revenue decreased by -5.25%.
  • Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 7.28% on average per year.
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 31.80% on average over the next years. This is a very strong growth
  • ALKS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.16% yearly.
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. ALKS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.54, the valuation of ALKS can be described as correct.
  • Based on the Price/Earnings ratio, ALKS is valued cheaply inside the industry as 94.61% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.46, ALKS is valued a bit cheaper.
  • ALKS is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 16.54
Fwd PE N/A
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • 94.99% of the companies in the same industry are more expensive than ALKS, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, ALKS is valued cheaper than 97.88% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.87
EV/EBITDA 14.17
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • ALKS has a very decent profitability rating, which may justify a higher PE ratio.
  • A cheap valuation may be justified as ALKS's earnings are expected to decrease with -2.65% in the coming years.
PEG (NY)N/A
PEG (5Y)0.52
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALKS Dividend Analysis

5.1 Amount

  • No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKS Fundamentals: All Metrics, Ratios and Statistics

ALKERMES PLC

NASDAQ:ALKS (3/9/2026, 8:00:01 PM)

After market: 28.45 0 (0%)

28.45

-0.18 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners109.8%
Inst Owner Change2.03%
Ins Owners1.6%
Ins Owner Change5.8%
Market Cap4.74B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts81.67
Price Target44.69 (57.08%)
Short Float %10.94%
Short Ratio9.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.45%
Min EPS beat(2)-16.95%
Max EPS beat(2)59.84%
EPS beat(4)3
Avg EPS beat(4)31.82%
Min EPS beat(4)-16.95%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)15.4%
EPS beat(12)7
Avg EPS beat(12)24.7%
EPS beat(16)10
Avg EPS beat(16)139.34%
Revenue beat(2)1
Avg Revenue beat(2)3.48%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.47%
Min Revenue beat(4)-1.55%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.64%
Revenue beat(12)6
Avg Revenue beat(12)3.42%
Revenue beat(16)9
Avg Revenue beat(16)2.75%
PT rev (1m)0%
PT rev (3m)-0.14%
EPS NQ rev (1m)-491.83%
EPS NQ rev (3m)-616.77%
EPS NY rev (1m)-141.15%
EPS NY rev (3m)-140.46%
Revenue NQ rev (1m)2.72%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)-0.87%
Revenue NY rev (3m)-1.66%
Valuation
Industry RankSector Rank
PE 16.54
Fwd PE N/A
P/S 3.21
P/FCF 9.87
P/OCF 9.1
P/B 2.61
P/tB 2.73
EV/EBITDA 14.17
EPS(TTM)1.72
EY6.05%
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)2.88
FCFY10.13%
OCF(TTM)3.12
OCFY10.98%
SpS8.86
BVpS10.92
TBVpS10.41
PEG (NY)N/A
PEG (5Y)0.52
Graham Number20.55
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.47
F-Score6
WACC7.7%
ROIC/WACC1.42
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.76%
EPS 3Y71.6%
EPS 5Y31.92%
EPS Q2Q%-72.38%
EPS Next Y-135.86%
EPS Next 2Y-28.08%
EPS Next 3Y-2.65%
EPS Next 5Y31.8%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year21.99%
Revenue Next 2Y12.92%
Revenue Next 3Y10.71%
Revenue Next 5Y11.16%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.82%
EBIT Next 3Y26.72%
EBIT Next 5Y26.75%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 5 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -135.86% in the next year.